Prescription Anti-Inflammatory Therapies
Synthesised from Topical Corticosteroids, Hydrocortisone, Clobetasone Butyrate, Clobetasol Propionate, Fingertip Unit, Weekend Therapy, Stepped Care Approach, Wet Wrap Therapy, HPA Axis Suppression, Iatrogenic Cushing Syndrome, Skin Atrophy, Perioral Dermatitis, Steroid Phobia, Topical Steroid Withdrawal, Topical Calcineurin Inhibitors, Tacrolimus, Pimecrolimus, PEER Registry, Crisaborole, Roflumilast Cream, Tapinarof Cream, Ruxolitinib Cream, JAK Inhibitors, Dupilumab, LIBERTY AD PRESCHOOL, Conjunctivitis, Systemic Immunosuppressants, TREAT Trial, Phototherapy and Oral Antihistamines (see MOC-prescription-anti-inflammatory-therapies). Corresponds mainly to infranodus cluster 3 (
tcs,therapy,inhibitors).
Overview
When emollients alone do not control Atopic Dermatitis, Track B care adds anti-inflammatory medicine in steps. Under the NICE CG57 Stepped Care Approach, mild eczema gets mild Topical Corticosteroids (TCS). Moderate eczema gets moderate TCS, Topical Calcineurin Inhibitors (TCIs) or bandages. Severe eczema gets potent TCS, Phototherapy or systemic drugs. Emollients continue at every step, and treatment steps down once the flare settles. For toddlers the default first medicine is mild Hydrocortisone on the face, neck and nappy area. The step up is a moderate steroid such as Clobetasone Butyrate for short courses on the body. Very potent Clobetasol Propionate is for specialists only.
The evidence for TCS is strong. The 2022 Cochrane strategies review (Lax et al.; 104 RCTs) found that once-daily potent TCS is probably as effective as twice-daily, and that proactive Weekend Therapy cuts flares (NNT about 3) with no skin thinning in 1,050 participants. Measured harms in children who use TCS as directed are small. In the Axon 2021 umbrella review, 3.8% of children had reversible biochemical HPA Axis Suppression, with no evidence of growth suppression. Skin Atrophy was absent at all 210 treated sites in a paediatric dermoscopy study. Serious harm, such as Iatrogenic Cushing Syndrome, almost always follows months of unsupervised potent steroid, often under a nappy or hidden in Adulterated Herbal Creams. Parental fear is out of proportion to this record. Steroid Phobia affects about 20–80% of parents and roughly triples non-adherence, and the contested Topical Steroid Withdrawal narrative feeds it.
Since 2020 the steroid-free options for young children have grown quickly. Pimecrolimus is UK-licensed from 3 months and Tacrolimus 0.03% from 2 years. In the US, Crisaborole is licensed from 3 months, and Roflumilast Cream, Tapinarof Cream and Ruxolitinib Cream from 2 years. All four of these newer creams received strong recommendations in the AAD Pediatric Guideline 2026, but none is licensed in the UK, and crisaborole’s EU licence was withdrawn. For severe disease, Dupilumab is licensed from 6 months on the strength of the LIBERTY AD PRESCHOOL trial. Older Systemic Immunosuppressants remain off-label options, compared head-to-head in the TREAT Trial. Oral JAK Inhibitors are mostly limited to age 12 and over.
Key Entities
Topical Corticosteroids
evidence: strong. Potency runs from mild (hydrocortisone) to very potent (up to 600 times hydrocortisone) on the UK four-tier scale. The US uses seven groups. Ointments and occlusion increase absorption. Classifications disagree for some molecules (desonide, triamcinolone), which is an open conflict. Dosing uses the Fingertip Unit: about 0.5 g squeezed along an adult finger. A 1–2-year-old needs about 1.5 FTU for face and neck and 3 FTU for the back, or roughly 7 g for the whole body. DermNet and Patient.info disagree on the face dose at 3–5 years. The FTU addresses two opposite errors: a thin smear driven by fear, and overuse of potent cream on thin skin.
Hydrocortisone, Clobetasone Butyrate and Clobetasol Propionate
Hydrocortisone (UK mild; US group VII) is the toddler default for face, folds and nappy-area eczema. UK over-the-counter hydrocortisone is for age 10 and over, and the US OTC label says “under 2 do not use” and “not for diaper rash”. This sits awkwardly with clinician advice to use it in exactly those sites, an unresolved conflict. Clobetasone (Eumovate, moderate) can be bought OTC only from age 12, so toddlers need a prescription. Its leaflet limits children to 7-day courses, while NICE reviews at 7–14 days. Clobetasol (Dermovate, very potent) should not be used in children without specialist advice. It is the steroid in most paediatric Cushing and adrenal-suppression case reports, including an 11-month-old given it 6–7 times a day for nappy rash who was left with hypertension and growth failure. The two names differ by a few letters and are easily confused.
Undeclared steroid in "natural" creams
Clobetasol and clobetasone have been found in unlabelled “herbal” eczema creams. A “steroid-free” cream that works dramatically and then causes a severe flare when stopped may contain a hidden potent steroid. Do not stop suddenly after long heavy use; see a doctor and bring the product.
Weekend Therapy
evidence: moderate. After control, TCS is applied on two consecutive days a week to usual flare sites, or a TCI twice weekly on non-consecutive days. In Cochrane 2022 this reduced flares from about 576 to 248 per 1,000. Schmitt 2011 found proactive fluticasone (RR 0.46) probably outperformed proactive tacrolimus (RR 0.78) by indirect comparison. NICE CG57 suggests it for children with 2–3 flares a month. The South African algorithm uses it for four or more flares a year. Few toddlers were in the trials.
HPA Axis Suppression, Iatrogenic Cushing Syndrome and Skin Atrophy
These are the systemic and local harms parents fear. The Australasian consensus (Mooney 2015) found 25 paediatric adrenal-suppression case reports. Most involved clobetasol used for 1–17 months under nappies. It found no pathological suppression when TCS was used for routine eczema management. Atrophy reverses after stopping, but striae are permanent. Striae are rare and also common naturally during growth spurts. Cochrane found 26 possible thinning cases among 2,266 trial participants, most on very potent steroid, and TCS thinned skin more than TCIs (RR 4.86). Perioral Dermatitis is a related facial complication. Steroid exposure was found in 58–72% of paediatric cases, and inhaled-steroid residue from spacers counts. Treatment is to stop the steroid (“zero therapy”), and the condition is easily mistaken for an eczema flare.
Steroid Phobia and Topical Steroid Withdrawal
Steroid phobia is measured with the TOPICOP Scale. Prevalence depends on the instrument used (21–84%). Non-adherence was 49.4% in phobic parents against 14.1% in others. In an Italian study, parents of children aged 4 and under scored lower, so the toddler years are the best time to give clear information. TSW is a patient-named reaction marked by burning, confluent redness and spread beyond treated sites. The MHRA (2021, 2024) and the 2024 UK joint statement accept it exists but call it rare. The Hajar 2015 review found reports almost entirely from the face or genitals of adult women misusing potent TCS (very low-quality evidence), and only about 21 child cases have been published. evidence: contested. Its online offshoot, No Moisture Therapy, is untested and risky for toddlers.
Topical Calcineurin Inhibitors, Tacrolimus and Pimecrolimus
evidence: strong. These steroid-free calcineurin blockers do not thin skin, which suits the face and eyelids. The main side effect is burning for 15–20 minutes that settles within about a week. Licensing ages leave a gap for toddlers. Pimecrolimus is UK-licensed from 3 months (NICE TA82 still says 2+), tacrolimus 0.03% from 2 years, and tacrolimus is off-label under 2 everywhere. The 2006 FDA cancer boxed warning remains. The PEER Registry (7,457 children aged 2–17, 26,792 person-years) found a cancer standardised incidence ratio of 1.2 (CI 0.5–2.8) and no skin cancers, and Health Canada dropped its warning in 2019. PEER also found that more than 80% of registrants still had eczema symptoms or used treatment, a far bleaker picture than ALSPAC, probably because of selection.
Newer steroid-free creams
Crisaborole is a PDE4 ointment, US-licensed from 3 months. Its infant study (CrisADe CARE 1) was open-label, and its EU licence was withdrawn in 2022. Roflumilast Cream 0.05% is a once-daily PDE4 cream licensed in the US for ages 2–5 since October 2025 (INTEGUMENT-PED, n=652: 25.4% vs 10.7% clear or almost clear). Tapinarof Cream is an AhR agonist licensed in the US from age 2 since December 2024. It is the only one of these creams with high-certainty AAD evidence, but causes Folliculitis in 9%. Ruxolitinib Cream is a topical JAK1/2 inhibitor licensed in the US from age 2 since September 2025 (TRuE-AD3: 60.6% vs 15.2% success at ages 2–6). It is second-line only, carries the JAK boxed warning, and is limited to 20% of body surface and 60 g per 2 weeks. None of the four has been compared with a mild steroid, and none is available in the UK.
Dupilumab and LIBERTY AD PRESCHOOL
evidence: strong. Dupilumab is an IL-4Rα antibody that blocks the Th2 Immune Response and restores Filaggrin expression in AD skin. LIBERTY AD PRESCHOOL randomised 162 children aged 6 months to under 6 years. At week 16, 28% vs 4% were clear or almost clear, and 53% vs 11% reached EASI-75. Over 2 years of open-label follow-up, 92% had clear-to-mild disease but only 27% were clear or almost clear. The US licence covers moderate-to-severe AD from 6 months. The EU licence covers severe AD only. Dupilumab is given by injection every 4 weeks without routine blood monitoring. Its main specific side effect is Conjunctivitis (5% at 16 weeks, 19% over 2 years in under-6s, all mild or moderate), thought to follow IL-13 blockade of conjunctival goblet cells.
Systemic Immunosuppressants and the TREAT Trial
Ciclosporin and methotrexate are off-label in children. TREAT (n=103, aged 2–16) found ciclosporin faster (EASI-75 at week 12: 44% vs 20%) and methotrexate more durable after stopping. Serious adverse events affected 10–14%, including one case of Eczema Herpeticum in each arm. Both drugs need blood monitoring. Results are not reported separately for under-5s, and the trial predates dupilumab. JAK Inhibitors taken by mouth (abrocitinib, upadacitinib) are licensed from age 12. Baricitinib is EU-licensed from age 2 but has no US eczema indication, an unresolved conflict. All carry 2021 boxed warnings derived from older adults with rheumatoid arthritis.
Phototherapy and Oral Antihistamines
Narrowband UVB evidence in children is observational. Data start at age 4, with clearance rates ranging from 25% to 90%. The BAD says it is “not usually recommended for children”, so it is rarely used in toddlers. Oral antihistamines do not treat eczema. Cochrane 2019 (25 RCTs) found no convincing benefit, including an 18-month cetirizine trial in 795 young children. NICE allows a 7–14 day sedating trial for sleep in children over 6 months. The MHRA bars OTC cough and cold use of sedating antihistamines such as Chlorphenamine under age 6, and paradoxical excitation is a risk. Wet Wrap Therapy over steroid is a specialist-guided option for severe flares. NICE limits whole-body steroid wraps to 7–14 days because occlusion raises absorption.
Connections Within This Community
Hydrocortisone [part-of] Topical Corticosteroids Clobetasone Butyrate [part-of] Topical Corticosteroids Clobetasol Propionate [causes] Iatrogenic Cushing Syndrome Clobetasol Propionate [causes] HPA Axis Suppression Fingertip Unit [defines] Topical Corticosteroids Weekend Therapy [prevents] Atopic Dermatitis Topical Corticosteroids [causes] Skin Atrophy Topical Corticosteroids [causes] Perioral Dermatitis Steroid Phobia [opposes] Topical Corticosteroids Topical Steroid Withdrawal [relates] Steroid Phobia Tacrolimus [part-of] Topical Calcineurin Inhibitors Pimecrolimus [part-of] Topical Calcineurin Inhibitors PEER Registry [supports] Pimecrolimus Ruxolitinib Cream [part-of] JAK Inhibitors LIBERTY AD PRESCHOOL [supports] Dupilumab Dupilumab [causes] Conjunctivitis TREAT Trial [supports] Systemic Immunosuppressants Stepped Care Approach [defines] Phototherapy
Bridges to Other Communities
- MOC-emollients-and-skin-care: Emollient Therapy continues at every step and reduces steroid needs. Soak and Seal and Wet Wrap Therapy deliver TCS to the skin.
- MOC-parent-experience-and-outcomes: Steroid Phobia, Topical Steroid Withdrawal and Online Parenting Forums shape adherence. The infranodus Gap 4 (
tcs↔toddler/parents) points to this weak link between the TCS evidence base and what parents actually do. Written Eczema Action Plan and Eczema Education Programmes are the tools that bridge it. - MOC-home-and-herbal-remedies: Adulterated Herbal Creams containing hidden clobetasol link Track A products to TCS harms. Parents who turn to “natural” care often do so because of steroid phobia.
- MOC-disease-and-mechanisms: dupilumab, TCIs and JAK inhibitors target the Th2 Immune Response. Filaggrin status did not change TREAT outcomes.
- MOC-infection: TCIs are not used on infected skin, systemic immunosuppression carries a risk of Eczema Herpeticum, and Fucidin H combines a steroid with an antibiotic.
- MOC-diagnosis-and-differentials: Perioral Dermatitis and Nappy Rash are steroid-sensitive mimics. Severity scores such as EASI and SCORAD set the trial endpoints.
- MOC-evidence-base-and-guidance: licensing differs between the FDA, European Medicines Agency, MHRA and SAHPRA. NICE CG57 and the AAD Pediatric Guideline 2026 give different recommendations for the newer creams.
Open Questions
- topical-corticosteroids-questions
- topical-corticosteroids-conflicts
- tcs-practicalities-questions
- tcs-practicalities-conflicts
- proactive-therapy-questions
- proactive-therapy-conflicts
- steroid-phobia-tsw-questions
- steroid-phobia-tsw-conflicts
- advanced-therapies-questions
- advanced-therapies-conflicts
- testing-phototherapy-questions
- testing-phototherapy-conflicts
- Gap-derived (tcs ↔ toddler): How do the new US steroid-free creams (roflumilast 0.05%, tapinarof, ruxolitinib) compare head-to-head with mild hydrocortisone in 1–4-year-olds, on effect and on parental adherence?
- Gap-derived (cochrane ↔ nice): When will NICE CG57 update its TCI age wording (pimecrolimus from 3 months) and consider the newer non-steroid creams that the AAD now strongly recommends?